Symptom severity is a major determinant of cannabis‐based products use among people with multiple sclerosis

Author:

Barré Tangui1ORCID,Testa Damien2,Santos Melina1,Marcellin Fabienne1,Roux Perrine1,Carrieri Patrizia1,Radoszycki Lise2,Protopopescu Camelia1

Affiliation:

1. Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM Marseille France

2. Carenity Paris France

Abstract

AbstractAims and ObjectivesWe aimed to identify correlates of cannabinoid‐based products (CBP) use in patients with multiple sclerosis (MS) in France and Spain.BackgroundMS is responsible for a wide range of symptoms, including pain. Access to CBP differs according to local legislation. The French context is more restrictive than the Spanish one, and no data regarding cannabis use among MS patients has yet been published. Characterizing MS patients who use CBP constitutes a first step toward identifying persons most likely to benefit from them.DesignAn online cross‐sectional survey was submitted to MS patients who were members of a social network for people living with chronic diseases and were living in France or Spain.MethodsTwo study outcomes measured therapeutic CBP use and daily therapeutic CBP use. Seemingly unrelated bivariate probit regression models were used to test for associations between the outcomes and patients’ characteristics while accounting for country‐related differences. STROBE guidelines were followed in reporting this study.ResultsAmong 641 study participants (70% from France), the prevalence of CBP use was similar in both countries (23.3% in France vs. 20.1% in Spain). MS‐related disability was associated with both outcomes, with a gradient observed between different degrees of disability. MS‐related pain level was associated with CBP use only.ConclusionsCBP use is common in MS patients from both countries. The more severe the MS, the more participants turned to CBP to alleviate their symptoms. Easier access to CBP should be ensured for MS patients in need of relief, especially from pain.Relevance to clinical practiceThis study highlights the characteristics of MS patients using CBP. Such practices should be discussed by healthcare professional with MS patients.

Publisher

Wiley

Subject

General Medicine,General Nursing

Reference59 articles.

1. Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America

2. Agence Nationale de Sécurité du Médicament et des Produits de Santé. (2014).Résumé des Caractéristiques du Produit. Retrieved February 22 2022 fromhttp://agence‐prd.ansm.sante.fr/php/ecodex/rcp/R0242579.htm

3. Agence Nationale de Sécurité du Médicament et des Produits de Santé. (2021).Cadre et mise en oeuvre de l'expérimentation (Framework and implementation of the experimentation). Retrieved August 25 2021 fromhttps://ansm.sante.fr/dossiers‐thematiques/cannabis‐a‐usage‐medical/cadre‐et‐mise‐en‐oeuvre‐de‐lexperimentation‐du‐cannabis‐medical

4. Barriers to the wider adoption of medicinal Cannabis

5. Almirall. (2010).Sativex® receives regulatory authorisation in Spain. Retrieved July 6 2021 fromhttps://www.almirall.de/documents/portlet_file_entry/4257831/1401_EN_Spain_regulatory_approval_final_‐with_MRP.pdf/953d6e94‐0343‐42e1‐9eff‐951cb30c9f48

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3